Article ; Online: Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil.
2019 Volume 74, Page(s) e771
Abstract: Objectives: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological referral centre in northeastern ... ...
| Abstract | Objectives: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological referral centre in northeastern Brazil. Methods: This was a retrospective cohort study of 36 patients diagnosed with MDS and treated with EPO alfa at 30,000 to 60,000 IU per week. Clinical data were collected from medical records. The events assessed were non-response to treatment and progression to acute myeloid leukaemia (AML). Statistical analyses were performed using GraphPad Prism 7 and SPSS 24 software. Results: The overall survival of patients who received EPO alfa treatment was 51.64%, with a median of 65 months of treatment, and the overall survival of this group was 100% during the first 24 months. We detected a 43.5-month median event-free survival, with a response rate of 80.5%. We observed responses from 25 to 175 months. Patients with transfusion dependence and those with a high-risk stratification, as determined by the International Prognostic Scoring System (IPSS), the Revised International Prognostic Scoring System (IPSS-R), the WHO classification-based Prognostic Scoring System (WPSS) and the WHO 2016, had a lower event-free survival than other patients. Conclusions: Despite the wide use of EPO alfa in the treatment of anaemia in patients with MDS, the median response duration is approximately only 24 months. Our data provide encouraging results concerning the benefits of using EPO alfa for the improvement of the quality of life, as patients treated with EPO showed higher overall survival, event-free survival rates and longer response durations than have been previously described in the literature. |
|---|---|
| MeSH term(s) | Aged ; Aged, 80 and over ; Blood Transfusion ; Brazil ; Disease Progression ; Epoetin Alfa/therapeutic use ; Female ; Hematinics/therapeutic use ; Hemoglobins/analysis ; Humans ; Kaplan-Meier Estimate ; Karyotype ; Male ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/mortality ; Platelet Count ; Progression-Free Survival ; Reference Values ; Retrospective Studies ; Risk Factors ; Time Factors ; Treatment Outcome |
| Chemical Substances | Hematinics ; Hemoglobins ; Epoetin Alfa (64FS3BFH5W) |
| Language | English |
| Publishing date | 2019-09-09 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2182801-5 |
| ISSN | 1980-5322 ; 1807-5932 |
| ISSN (online) | 1980-5322 |
| ISSN | 1807-5932 |
| DOI | 10.6061/clinics/2019/e771 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 404: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.